Skip to main content
4SC AG logo

4SC AG — Investor Relations & Filings

Ticker · VSC ISIN · DE000A3E5C40 LEI · 391200QOKN7LGVP0RQ86 F Manufacturing
Open in API
Filings indexed 719 across all filing types
Latest filing 2012-02-17 Regulatory Filings
Country DE Germany
Listing F VSC

About 4SC AG

https://www.4sc.com/

4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.

Recent filings

Filing Released Lang Actions
Press Release 4SC: New data on mode of action reinforce further development of vidofludimus in IBD
Regulatory Filings Classification · 99% confidence The document is a 'Press Release' dated February 17, 2012, detailing new preclinical data for the drug vidofludimus and mentioning upcoming poster presentations at a conference (ECCO IBD conference). It discusses scientific findings, future clinical study preparations, and provides company/contact information. This content is characteristic of a general corporate announcement regarding research progress, not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a general corporate news release about product development and scientific updates, and it doesn't fit the specific categories like M&A (TAR), Director's Dealing (DIRS), or Dividend (DIV), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate news announcements that are not covered by more specific codes.
2012-02-17 English
Declaration of Voting Results & Voting Rights Announcements 2012
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Veröffentlichung einer Stimmrechtsmitteilung' (Publication of a voting rights notification). It details that a shareholder, Roland Oetker, crossed the 3% threshold of voting rights in 4SC AG on February 15, 2012, citing German Securities Trading Act sections (§§ 21 Abs. 1, 22 Abs. 1 WpHG). This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers notifications of changes in significant share ownership or voting rights.
2012-02-16 German
4SC AG: Cancer compound resminostat meets primary endpoint in Phase II trial in advanced liver cancer ahead of schedule
Regulatory Filings Classification · 98% confidence The document is a press release dated January 19, 2012, announcing that 4SC AG's cancer compound resminostat met its primary endpoint in a Phase II clinical trial for advanced liver cancer. It details efficacy data (PFS, PFSR), safety profile, and mentions plans for a pivotal study program. It also announces a conference call and webcast to discuss these results. This content structure—announcing key clinical trial results, providing data summaries, and scheduling a call—is characteristic of an Earnings Release (ER) or a general press release detailing significant operational/clinical progress. Since it focuses purely on clinical trial results and company progress rather than comprehensive financial statements (like a 10-K or IR), and it is an initial announcement of results (not just a notice that a report is attached), the most appropriate classification is Earnings Release (ER), as clinical trial updates often accompany or substitute for quarterly financial updates in biotech/pharma contexts, focusing on performance metrics. It is not a 10-K (Annual Report), AR (Audit Report), IR (Interim Report), or MDA (Management Discussion & Analysis) because it lacks the comprehensive financial statements or mandated regulatory structure of those filings. It is not an RPA because it is the substantive announcement itself, not just a notice that a report is available.
2012-01-19 English
4SC AG: 4SC's cancer compound resminostat meets primary endpoint in Phase II trial in advanced liver cancer (HCC) ahead of schedule
Regulatory Filings Classification · 95% confidence The document is titled 'News Details' and is marked as 'Ad-hoc' with a date of '19 January 2012'. It announces that 4SC's cancer compound resminostat met its primary endpoint in a Phase II trial. The text explicitly states, 'Dissemination of an Ad hoc announcement according to § 15 WpHG'. This structure—a timely, material announcement outside of routine periodic filings—is characteristic of an immediate disclosure. Furthermore, the document concludes with information about an upcoming conference call and webcast to discuss the data, which is typical for an immediate press release regarding clinical trial results. This content is not a full Annual Report (10-K), an Interim Report (IR), or a formal Audit Report (AR). It is a press release detailing significant, non-periodic operational/clinical news. Since there is no specific category for 'Clinical Trial Result Announcement' or 'Press Release', the most appropriate fallback category for a material, non-periodic regulatory disclosure that doesn't fit other specific types (like M&A, Dividend, or Management Change) is 'Regulatory Filings' (RNS). However, given the nature of the content (a major clinical trial update), it often falls under a general 'Earnings Release' (ER) if it contains key financial/operational highlights, or sometimes a specific 'LTR' if it were a legal matter. Since this is a scientific/clinical update, and not a standard quarterly earnings release, RNS is the best fit as a general regulatory disclosure/announcement.
2012-01-19 English
Report Publication Announcement 2012
Report Publication Announcement Classification · 100% confidence The document is a short announcement dated January 9, 2012, from 4SC AG. It explicitly states that it is an 'Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG' and its objective is the 'Europe-wide distribution'. Crucially, the text does not contain the financial reports themselves but lists several future reports (Annual financial report, Half-year report, Quarterly reports) along with their planned disclosure dates and links to where they will be published. According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing the publication or availability of other reports should be classified as a Report Publication Announcement (RPA).
2012-01-09 English
Hinweis auf Quartalsfinanzbericht vom 01.01.2012 bis zum 30.09.2012
Report Publication Announcement Classification · 100% confidence The document is a short notification (754 characters) informing stakeholders that a quarterly financial report for the period 01.01.2012 to 30.09.2012 is available on the company's website. It does not contain the financial report itself, but rather acts as an announcement of its publication. Per the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2012-01-09 German

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.